AbbVie (ABBV) Announces FDA Approval of VUITY 1.25%, the First and Only Eye Drop to Treat Presbyopia

Abbvie (ABBV) PT Raised to $134 at BMO Capital

BMO Capital analyst Gary Nachman raised the price target on Abbvie (NYSE: ABBV) to $134.00 (from $133.00) while maintaining an Outperform rating.

The analyst commented, "3Q delivered solid results and showed benefits of improved diversification with good upside in Immunology, Aesthetics, and Neuro... More

Pre-Open Stock Movers 10/29: (X) (ATEN) (TEAM) Higher; (ZEN) (WDC) (MNTV) Lower (more...)

Pre-Open Stock Movers

Zendesk (NYSE: ZEN) 20.7% LOWER; Zendesk and Momentive (NASDAQ: MNTV) have entered into a definitive agreement under which Zendesk will acquire Momentive, including its iconic SurveyMonkey platform. The terms of the transaction provide for Momentive stockholders to receive 0.225 shares of Zendesk stock for each share of Momentive stock, a ratio which represents an implied value of approximately $28 per outstanding share of Momentive stock based on the 15-day volume weighted average price of Zendesk common stock up to and including October 26, 2021.

Western... More

AddVie (ABBV) Continues to Deliver, Despite Concerns - Analyst

Earlier today, AbbVie (NYSE: ABBV) reported its Q3 results: EPS of $3.33, $0.10 better than the analyst estimate of $3.23; Revenue of $14.34 billion versus the consensus estimate of $14.35 billion.

The company also raised its adjusted diluted EPS for the full-year 2021 from $12.52 to $12.62 to $12.63 to $12.67.

Commenting on the earnings readout, Mizuho analyst Vamil Divan is encouraged by the company's continued strong performance and outlook, even as he awaits greater clarity... More

AbbVie's (ABBV) Cariprazine Met Primary Endpoint in Phase 3 Study as an Adjunctive Treatment for Major Depressive Disorder

AbbVie (NYSE: ABBV) today announced top-line results from two Phase 3 clinical trials, Study 3111-301-001 and Study 3111-302-001, evaluating the efficacy and safety of cariprazine (VRAYLAR®) as an adjunctive treatment for patients with major depressive disorder (MDD). In Study 3111-301-001, cariprazine showed a statistically significant change from baseline to week six in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score compared with placebo. Patients treated with cariprazine at 1.5 mg/day achieved improved MADRS total score at week six compared to placebo (p-value=0.0050). Patients treated with cariprazine at 3.0 mg/day demonstrated... More

AbbVie (ABBV) Raises Quarterly Dividend 8.5% to $1.41; 5.1% Yield

AbbVie (NYSE: ABBV) declared a quarterly dividend of $1.41 per share, or $5.64 annualized. This is an 8.5% increase from the prior dividend of $1.30.

The dividend will be payable on February 15, 2022, to stockholders of record on January 14, 2022, with an ex-dividend date of January 13,... More

AbbVie (ABBV) Tops Q3 EPS by 10c, Offers Guidance

AbbVie (NYSE: ABBV) reported Q3 EPS of $3.33, $0.10 better than the analyst estimate of $3.23. Revenue for the quarter came in at $14.34 billion versus the consensus estimate of $14.35 billion.

GUIDANCE:

AbbVie sees FY2021 EPS of $12.63-$12.67, versus the consensus of... More

AbbVie (ABBV) call put ratio 8.8 calls to 1 put into quarter results

AbbVie (NYSE: ABBV) October weekly call option implied volatility is at 51, November is at 26; compared to its 52-week range of 18 to 40 into the expected release of quarter results before the bell on October 29. Call put ratio 8.8 calls to 1 put.

AbbVie (ABBV) Reports ABBV-951Showed Improvement in Controlling Motor Fluctuations Compared to Oral Levodopa/Carbidopa Medication in Pivotal Phase 3 Trial

AbbVie (NYSE: ABBV) today announced that continuous 24 hours/day subcutaneous infusion of ABBV-951 (foslevodopa/foscarbidopa) was statistically superior to oral levodopa/carbidopa in reducing motor fluctuations in patients with advanced Parkinson's disease (PD) in a Phase 3, randomized, double-blind, double-dummy, active-controlled study. The study met its primary endpoint of increase from baseline in "On" time (hours) without troublesome dyskinesia (involuntary movements) after 12 weeks based on the Parkinson's Disease Diary (PD Diary).1 These results will be a key component of global regulatory submissions.

The increase in "On" time at week 12 was 2.72 hours for ABBV-951 versus... More